Clinically, the application of this platform to BALF samples from lung cancer patients enabled accurate discrimination between ICI responders and non‐responders, outperforming tissue PD‐L1 IHC and conventional ELISA in predictive sensitivity and prognostic stratification (Figure 5). The gene discussed is CD274; the disease is lung cancer.